Trial Profile
Identification of Patients With High Probability of Not or Poorly Responding to Mycophenolate-mofetil (Cellcept) or Mycophenolate-natrium (Myfortic) Therapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Mycophenolate mofetil (Primary) ; Mycophenolate sodium (Primary)
- Indications Renal transplant rejection
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms MPASNPVienna
- 09 Sep 2020 Status changed from active, no longer recruiting to completed.
- 25 Dec 2017 Planned End Date changed from 1 Jun 2013 to 1 Dec 2018.
- 25 Dec 2017 Planned primary completion date changed from 1 Mar 2013 to 1 Dec 2018.